Literature DB >> 36262398

Radiolabeled Aminopyrazoles as Novel Isoform Selective Probes for pJNK3 Quantification.

Brian C Bales1, Victoria Cotero1, Dan E Meyer1, Jeannette C Roberts1, Monica Rodriguez-Silva2, Tiberiu M Siclovan1, Jeremy W Chambers2, Michael J Rishel1.   

Abstract

The c-Jun N-terminal kinase 3 (JNK3) is a stress-activated kinase primarily expressed in the brain and implicated as an early mediator of neuronal apoptosis. We sought to develop a PET tracer to visualize pathological JNK3 activation. Because regional JNK3 activation precedes apoptosis, such an imaging agent might enable the detection of "at risk" brain regions prior to neuronal death. We prepared a set of 19F-containing compounds on the basis of the reported aminopyrazoles. The candidate, F3, was tritiated and used in autoradiography experiments to demonstrate regional and temporal changes in JNK3 activation in a mouse model of Parkinson's disease. A significant increase in pJNK3 B max versus control animals in multiple brain regions was observed at 8 months, including the ventral midbrain. Pathological activation of JNK3 in these regions preceded statistically significant neuron loss. Analyses of brain concentrations of [18F]-F3 in naïve rats following intravenous injection revealed a small but detectable signal over the background, but was likely not sufficient to support PET imaging.
© 2022 American Chemical Society.

Entities:  

Year:  2022        PMID: 36262398      PMCID: PMC9575163          DOI: 10.1021/acsmedchemlett.2c00278

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.632


  55 in total

1.  Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment.

Authors:  R D Terry; E Masliah; D P Salmon; N Butters; R DeTeresa; R Hill; L A Hansen; R Katzman
Journal:  Ann Neurol       Date:  1991-10       Impact factor: 10.422

2.  Small Molecule c-jun-N-terminal Kinase (JNK) Inhibitors Protect Dopaminergic Neurons in a Model of Parkinson's Disease.

Authors:  Jeremy W Chambers; Alok Pachori; Shannon Howard; Michelle Ganno; Donald Hansen; Ted Kamenecka; Xinyi Song; Derek Duckett; Weimin Chen; Yuan Yuan Ling; Lisa Cherry; Michael D Cameron; Li Lin; Claudia H Ruiz; Philip Lograsso
Journal:  ACS Chem Neurosci       Date:  2011-04-20       Impact factor: 4.418

3.  Small molecule JNK (c-Jun N-terminal kinase) inhibitors.

Authors:  M Arshad Siddiqui; Panduranga A Reddy
Journal:  J Med Chem       Date:  2010-04-22       Impact factor: 7.446

4.  Semaphorin 3A and neurotrophins: a balance between apoptosis and survival signaling in embryonic DRG neurons.

Authors:  Ayal Ben-Zvi; Zohar Yagil; Yamit Hagalili; Hagit Klein; Omer Lerman; Oded Behar
Journal:  J Neurochem       Date:  2005-12-08       Impact factor: 5.372

5.  Increased levels of cerebrospinal fluid JNK3 associated with amyloid pathology: links to cognitive decline.

Authors:  Sarah Gourmaud; Claire Paquet; Julien Dumurgier; Clarisse Pace; Constantin Bouras; Françoise Gray; Jean-Louis Laplanche; Eliane F Meurs; François Mouton-Liger; Jacques Hugon
Journal:  J Psychiatry Neurosci       Date:  2015-05       Impact factor: 6.186

6.  Phosphorylated mitogen-activated protein kinase (MAPK/ERK-P), protein kinase of 38 kDa (p38-P), stress-activated protein kinase (SAPK/JNK-P), and calcium/calmodulin-dependent kinase II (CaM kinase II) are differentially expressed in tau deposits in neurons and glial cells in tauopathies.

Authors:  I Ferrer; R Blanco; M Carmona; B Puig
Journal:  J Neural Transm (Vienna)       Date:  2001       Impact factor: 3.575

7.  High throughput artificial membrane permeability assay for blood-brain barrier.

Authors:  Li Di; Edward H Kerns; Kristi Fan; Oliver J McConnell; Guy T Carter
Journal:  Eur J Med Chem       Date:  2003-03       Impact factor: 6.514

8.  A chromatin-modifying function of JNK during stem cell differentiation.

Authors:  Vijay K Tiwari; Michael B Stadler; Christiane Wirbelauer; Renato Paro; Dirk Schübeler; Christian Beisel
Journal:  Nat Genet       Date:  2011-12-18       Impact factor: 38.330

9.  D-JNKI1, a cell-penetrating c-Jun-N-terminal kinase inhibitor, protects against cell death in severe cerebral ischemia.

Authors:  Lorenz Hirt; Jérôme Badaut; Jonathan Thevenet; Cristina Granziera; Luca Regli; Fabienne Maurer; Christophe Bonny; Julien Bogousslavsky
Journal:  Stroke       Date:  2004-06-03       Impact factor: 7.914

10.  Design and synthesis of highly potent and isoform selective JNK3 inhibitors: SAR studies on aminopyrazole derivatives.

Authors:  Ke Zheng; Sarah Iqbal; Pamela Hernandez; HaJeung Park; Philip V LoGrasso; Yangbo Feng
Journal:  J Med Chem       Date:  2014-11-21       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.